ECSP23050553A - Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma - Google Patents

Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma

Info

Publication number
ECSP23050553A
ECSP23050553A ECSENADI202350553A ECDI202350553A ECSP23050553A EC SP23050553 A ECSP23050553 A EC SP23050553A EC SENADI202350553 A ECSENADI202350553 A EC SENADI202350553A EC DI202350553 A ECDI202350553 A EC DI202350553A EC SP23050553 A ECSP23050553 A EC SP23050553A
Authority
EC
Ecuador
Prior art keywords
carboxamide
formula
indazole
pyridazin
imidazo
Prior art date
Application number
ECSENADI202350553A
Other languages
English (en)
Spanish (es)
Inventor
Yafeng Xue
Ina Terstiege
Stefan Schiesser
Hui-Fang Chang
Anna Ingrid Kristina Berggren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP23050553A publication Critical patent/ECSP23050553A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ECSENADI202350553A 2020-12-10 2023-07-05 Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma ECSP23050553A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063199160P 2020-12-10 2020-12-10

Publications (1)

Publication Number Publication Date
ECSP23050553A true ECSP23050553A (es) 2023-08-31

Family

ID=79230946

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202350553A ECSP23050553A (es) 2020-12-10 2023-07-05 Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma

Country Status (33)

Country Link
US (3) US11866405B2 (cg-RX-API-DMAC7.html)
EP (1) EP4259632B1 (cg-RX-API-DMAC7.html)
JP (1) JP7749015B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230118153A (cg-RX-API-DMAC7.html)
CN (1) CN116583285B (cg-RX-API-DMAC7.html)
AR (1) AR124303A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021395816B2 (cg-RX-API-DMAC7.html)
CA (1) CA3203569A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001662A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007624A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230264A (cg-RX-API-DMAC7.html)
DK (1) DK4259632T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000119A (cg-RX-API-DMAC7.html)
EC (1) ECSP23050553A (cg-RX-API-DMAC7.html)
ES (1) ES2989489T3 (cg-RX-API-DMAC7.html)
FI (1) FI4259632T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241312T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068584T2 (cg-RX-API-DMAC7.html)
IL (1) IL303356B2 (cg-RX-API-DMAC7.html)
LT (1) LT4259632T (cg-RX-API-DMAC7.html)
MA (1) MA62535B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006816A (cg-RX-API-DMAC7.html)
PE (1) PE20240684A1 (cg-RX-API-DMAC7.html)
PL (1) PL4259632T3 (cg-RX-API-DMAC7.html)
PT (1) PT4259632T (cg-RX-API-DMAC7.html)
RS (1) RS66095B1 (cg-RX-API-DMAC7.html)
SI (1) SI4259632T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400417T1 (cg-RX-API-DMAC7.html)
TW (1) TWI902994B (cg-RX-API-DMAC7.html)
UA (1) UA130417C2 (cg-RX-API-DMAC7.html)
UY (1) UY39561A (cg-RX-API-DMAC7.html)
WO (1) WO2022122876A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306848B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023152349A1 (en) * 2022-02-14 2023-08-17 Astrazeneca Ab Irak4 inhibitors
US20250326757A1 (en) * 2022-05-26 2025-10-23 Astrazeneca Ab Solid forms of heterocyclylamides as irak4 inhibitors
US20240374588A1 (en) 2023-04-07 2024-11-14 Astrazeneca Ab Irak4 protacs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体
HUE029617T2 (en) 2010-12-20 2017-03-28 Merck Serono Sa Indazolyl triazole derivatives as IRAK inhibitors
BG111378A (bg) * 2013-01-14 2015-01-30 Николай Цветков Субституирани индазолови производни като in-vitro mao-b инхибитори
RU2665554C2 (ru) * 2013-03-15 2018-08-31 Байомарин Фармасьютикал Инк. Ингибиторы hdac
HK1231480A1 (zh) 2014-01-10 2017-12-22 Aurigene Discovery Technologies Limited 作为irak4抑制剂的吲唑化合物
PL3536685T3 (pl) 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
CA2992406A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
EP3322409A4 (en) 2015-07-15 2019-07-24 Aurigene Discovery Technologies Limited SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS
CN105503863A (zh) * 2015-12-11 2016-04-20 南京华威医药科技开发有限公司 新型抗肿瘤化合物
EP3394066A2 (en) 2015-12-22 2018-10-31 H. Hoffnabb-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
US10059708B2 (en) 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
WO2017207386A1 (de) 2016-06-01 2017-12-07 Bayer Pharma Aktiengesellschaft Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen
JP2020524692A (ja) 2017-06-21 2020-08-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Irak4調節因子としてのベンゾフラン
CN110785418A (zh) 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 作为irak4调节剂的异二氢吲哚酮衍生物
KR20220027196A (ko) 2019-06-27 2022-03-07 바이오젠 엠에이 인코포레이티드 이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도
CN114585609B (zh) 2019-06-27 2024-07-30 比奥根Ma公司 2h-吲唑衍生物及其在疾病治疗中的用途

Also Published As

Publication number Publication date
DK4259632T3 (da) 2024-10-21
UA130417C2 (uk) 2026-02-11
IL303356B1 (en) 2026-04-01
HRP20241312T1 (hr) 2024-12-20
LT4259632T (lt) 2024-10-10
EP4259632B1 (en) 2024-07-24
PE20240684A1 (es) 2024-04-10
PT4259632T (pt) 2024-10-24
CL2023001662A1 (es) 2024-01-12
JP7749015B2 (ja) 2025-10-03
KR20230118153A (ko) 2023-08-10
ES2989489T3 (es) 2024-11-26
AU2021395816B2 (en) 2024-04-04
WO2022122876A1 (en) 2022-06-16
AR124303A1 (es) 2023-03-15
US20220185817A1 (en) 2022-06-16
AU2021395816A9 (en) 2025-03-13
ZA202306848B (en) 2024-04-24
CN116583285A (zh) 2023-08-11
IL303356A (en) 2023-08-01
HUE068584T2 (hu) 2025-01-28
FI4259632T3 (fi) 2024-10-24
TW202237612A (zh) 2022-10-01
EP4259632A1 (en) 2023-10-18
UY39561A (es) 2022-06-30
US11866405B2 (en) 2024-01-09
MX2023006816A (es) 2023-06-21
RS66095B1 (sr) 2024-11-29
US20240182479A1 (en) 2024-06-06
MA62535B1 (fr) 2024-11-29
CA3203569A1 (en) 2022-06-16
US20260092069A1 (en) 2026-04-02
CR20230264A (es) 2023-07-26
SI4259632T1 (sl) 2024-12-31
IL303356B2 (en) 2026-08-01
CO2023007624A2 (es) 2023-06-30
PL4259632T3 (pl) 2024-12-16
SMT202400417T1 (it) 2024-11-15
CN116583285B (zh) 2026-03-24
US12448385B2 (en) 2025-10-21
TWI902994B (zh) 2025-11-01
AU2021395816A1 (en) 2023-07-13
DOP2023000119A (es) 2023-07-09
JP2023552838A (ja) 2023-12-19

Similar Documents

Publication Publication Date Title
CL2023001662A1 (es) Derivados de 1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma
CN115925705B (zh) 杂芳类衍生物调节剂、其制备方法和应用
JP6096778B2 (ja) ピロロピラジンキナーゼ阻害剤
CN102711476B (zh) 新的三环化合物
PE20211001A1 (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
RU2014115478A (ru) Новые гетероциклические производные и их применения
EP2118108B1 (en) Compounds for the treatment of hepatitis c
JP2014531458A5 (cg-RX-API-DMAC7.html)
JP6467404B2 (ja) P2x7モジュレーター
RU2015131148A (ru) СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ
KR20200074178A (ko) 염증 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물
CA2681093A1 (en) Compounds for the treatment of hepatitis c
MX2013003913A (es) Compuestos de furo [3, 2-d] pirimidina.
WO2012149280A2 (en) Novel tricyclic compounds
CA2713718A1 (en) Pyrrolopyrazine kinase inhibitors
MX2012006381A (es) Nuevos compuestos triciclicos.
WO2009152133A1 (en) Novel tricyclic compounds
JP2011513261A (ja) ピロロピラジンキナーゼ阻害剤
Dyachenko et al. Fused pyrimidine systems: XIII. Synthesis and some transformations of 1, 3-thiazolo (thiazino)-fused pyrido [3, 4-d] pyrimidines
JP2018150349A5 (cg-RX-API-DMAC7.html)
RU2017103508A (ru) Трициклические триазольные соединения
EA052277B1 (ru) Трициклические гетероциклические производные, их композиции и использование
ECSP961759A (es) 5,6 dihidro -9h- pirazol (3,4-c)-1,2,4- triazol (4- 3 -a) piridinas triciclicas